Theyre less likely to get put on blood pressure-lowering medications
Recently, a high-resolution crystal structure of phosphinic pseudopeptide inhibitor 45 (DG046) in the closed-conformation of ERAP1 was disclosed (Giastas et al., 2019b) and a mechanism for antigen peptide selection by ERAP1 presented (Giastas et al., 2019a)
W.MartinezJ
Despite this, it should be noted that patient numbers in certain background medication subgroups were relatively low
Kim Y, Keogh JB, Clifton PM
As patents expire and potential generic or biosimilar versions emerge (e.g., generic liraglutide by Teva in 2024 ( [68] )), costs might come down, but for newer agents like semaglutide or tirzepatide, it could be years